DK0948358T3 - Stabile inteferon-væskeformuleringer - Google Patents

Stabile inteferon-væskeformuleringer

Info

Publication number
DK0948358T3
DK0948358T3 DK97952621T DK97952621T DK0948358T3 DK 0948358 T3 DK0948358 T3 DK 0948358T3 DK 97952621 T DK97952621 T DK 97952621T DK 97952621 T DK97952621 T DK 97952621T DK 0948358 T3 DK0948358 T3 DK 0948358T3
Authority
DK
Denmark
Prior art keywords
liquid
interferon
compositions
inteferon
stable
Prior art date
Application number
DK97952621T
Other languages
English (en)
Other versions
DK0948358T4 (da
Inventor
Mary D Dibiasi
Mark Staples
Wen-Li Chung
Eric Scharin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0948358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of DK0948358T3 publication Critical patent/DK0948358T3/da
Application granted granted Critical
Publication of DK0948358T4 publication Critical patent/DK0948358T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK97952621.7T 1996-12-24 1997-12-23 Stabile inteferon-væskeformuleringer DK0948358T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (2)

Publication Number Publication Date
DK0948358T3 true DK0948358T3 (da) 2004-11-08
DK0948358T4 DK0948358T4 (da) 2012-03-19

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97952621.7T DK0948358T4 (da) 1996-12-24 1997-12-23 Stabile inteferon-væskeformuleringer

Country Status (28)

Country Link
EP (1) EP0948358B2 (da)
JP (5) JP4878664B2 (da)
KR (2) KR20000069664A (da)
CN (2) CN1733296B (da)
AT (1) ATE270899T1 (da)
AU (1) AU738362B2 (da)
BG (2) BG65171B1 (da)
BR (1) BR9714434A (da)
CA (1) CA2275890C (da)
CZ (1) CZ300636B6 (da)
DE (1) DE69729880T3 (da)
DK (1) DK0948358T4 (da)
EA (1) EA002754B1 (da)
EE (2) EE04266B1 (da)
ES (1) ES2224290T5 (da)
HK (2) HK1025040A1 (da)
HU (1) HU224222B1 (da)
IL (1) IL130524A (da)
IS (1) IS2070B (da)
MX (1) MX337876B (da)
NO (1) NO327844B1 (da)
NZ (2) NZ336548A (da)
PL (1) PL193447B1 (da)
PT (1) PT948358E (da)
SI (1) SI0948358T2 (da)
SK (1) SK284989B6 (da)
TR (1) TR199901968T2 (da)
WO (1) WO1998028007A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EA002754B1 (ru) * 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона
EP1224940B2 (de) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
JP4635340B2 (ja) * 1999-05-31 2011-02-23 三菱化学株式会社 Ｈｇｆ凍結乾燥製剤
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
HUP0402315A3 (en) 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
AU2004241698A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP3378470A1 (en) 2003-12-19 2018-09-26 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
JP2008500995A (ja) * 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
BRPI0514408B8 (pt) * 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4891250B2 (ja) * 2004-11-10 2012-03-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 脱アミドされたインターフェロンβ
PL1845925T3 (pl) * 2005-01-12 2017-05-31 Biogen Ma Inc. Sposób podawania interferonu beta
JP2008528509A (ja) * 2005-01-21 2008-07-31 アルザ コーポレイション 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤
EP2264161A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
DK2234645T3 (da) 2007-12-20 2012-07-09 Merck Serono Sa Peg-interferon-beta-formuleringer
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN102066401A (zh) 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2788863C (en) 2010-02-04 2020-07-07 Reinhard Franz Bolli Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR20130132496A (ko) * 2010-12-09 2013-12-04 마루이시세이야쿠가부시키가이샤 아세트아미노펜의 안정화제
PL2686002T3 (pl) 2011-03-15 2018-10-31 Biogen Ma Inc. Sposób łagodzenia symptomów grypopodobnych związanych z domięśniowym podawaniem interferonu przy wykorzystaniu schematu zwiększania dawki z szybkim miareczkowaniem
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2838571A4 (en) * 2012-04-19 2016-02-10 Bard Inc C R INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
CN115989239A (zh) * 2020-04-29 2023-04-18 瑷备恩有限公司 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
WO2023129502A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (da) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
EA002754B1 (ru) * 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона

Also Published As

Publication number Publication date
HK1025040A1 (en) 2000-11-03
NZ512792A (en) 2002-11-26
EE04223B1 (et) 2004-02-16
EP0948358B2 (en) 2011-11-23
JP5851695B2 (ja) 2016-02-03
NZ336548A (en) 2001-09-28
AU5619198A (en) 1998-07-17
EP0948358B1 (en) 2004-07-14
SK85899A3 (en) 2000-01-18
SI0948358T1 (en) 2005-04-30
ES2224290T3 (es) 2005-03-01
CA2275890C (en) 2011-11-01
JP2011068694A (ja) 2011-04-07
BG109523A (en) 2007-05-31
NO993121D0 (no) 1999-06-23
IS2070B (is) 2005-12-15
HK1092048A1 (en) 2007-02-02
CN1222315C (zh) 2005-10-12
JP2012006979A (ja) 2012-01-12
SK284989B6 (sk) 2006-04-06
DK0948358T4 (da) 2012-03-19
BG65171B1 (bg) 2007-05-31
CN1733296A (zh) 2006-02-15
JP4878664B2 (ja) 2012-02-15
EE200300127A (et) 2003-06-16
BR9714434A (pt) 2000-05-02
EE9900313A (et) 2000-04-17
MX337876B (es) 2016-03-22
CN1245434A (zh) 2000-02-23
IL130524A (en) 2005-08-31
JP2007204501A (ja) 2007-08-16
BG65418B1 (bg) 2008-07-31
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
BG103594A (en) 2000-04-28
NO993121L (no) 1999-08-24
HU224222B1 (hu) 2005-06-28
KR101042660B1 (ko) 2011-06-20
CA2275890A1 (en) 1998-07-02
KR20070052363A (ko) 2007-05-21
DE69729880T3 (de) 2012-05-10
WO1998028007A1 (en) 1998-07-02
EA002754B1 (ru) 2002-08-29
EP0948358A1 (en) 1999-10-13
PL334365A1 (en) 2000-02-28
JP2001519770A (ja) 2001-10-23
HUP0000829A2 (en) 2000-07-28
IL130524A0 (en) 2000-06-01
SI0948358T2 (sl) 2012-03-30
AU738362B2 (en) 2001-09-13
DE69729880D1 (de) 2004-08-19
CN1733296B (zh) 2010-05-26
DE69729880T2 (de) 2005-07-07
HUP0000829A3 (en) 2002-01-28
NO327844B1 (no) 2009-10-05
PL193447B1 (pl) 2007-02-28
ATE270899T1 (de) 2004-07-15
EE04266B1 (et) 2004-04-15
IS5087A (is) 1999-06-21
TR199901968T2 (xx) 1999-12-21
PT948358E (pt) 2004-10-29
EA199900597A1 (ru) 2000-02-28
ES2224290T5 (es) 2012-03-12
KR20000069664A (ko) 2000-11-25
CZ300636B6 (cs) 2009-07-08

Similar Documents

Publication Publication Date Title
DK0948358T3 (da) Stabile inteferon-væskeformuleringer
CA2085750A1 (en) Osteoinductive pharmaceutical formulations
CA2032499A1 (en) Polypeptide derivatives
DE69604147D1 (de) Flüssige zuzammensetzung zur stabilisierung von aminosäure-herbiziden
ATE187062T1 (de) Formulierungen zum suspendieren: von proteine und peptiden
GR3035067T3 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins.
CA2061569A1 (en) Improved activation of recombinant proteins
DE68920931D1 (de) Rekombinanter natürlicher Killerzellen-Aktivator.
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
JPS51125790A (en) Carrier for fixing of biologically active substances
MX9709907A (es) Formulaciones de suspension de peptido/proteina.
NZ509773A (en) Casein formulations for the delivery of bioactive constituents